Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more
Market Cap & Net Worth: Molecular Partners AG (MLLCF)
Molecular Partners AG (PINK:MLLCF) has a market capitalization of $157.82 Million ($157.82 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #19503 globally and #7165 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Molecular Partners AG's stock price $4.22 by its total outstanding shares 37399152 (37.40 Million).
Molecular Partners AG Market Cap History: 2018 to 2025
Molecular Partners AG's market capitalization history from 2018 to 2025. Data shows change from $724.05 Million to $157.82 Million (-21.85% CAGR).
Molecular Partners AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Molecular Partners AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
34.09x
Molecular Partners AG's market cap is 34.09 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $724.05 Million | $10.36 Million | -$37.04 Million | 69.92x | N/A |
| 2019 | $527.33 Million | $20.38 Million | -$36.29 Million | 25.87x | N/A |
| 2020 | $882.25 Million | $9.34 Million | -$62.76 Million | 94.42x | N/A |
| 2021 | $739.94 Million | $9.33 Million | -$63.78 Million | 79.31x | N/A |
| 2022 | $230.75 Million | $189.56 Million | $117.85 Million | 1.22x | 1.96x |
| 2023 | $160.82 Million | $7.04 Million | -$61.98 Million | 22.85x | N/A |
| 2024 | $169.42 Million | $4.97 Million | -$54.04 Million | 34.09x | N/A |
Competitor Companies of MLLCF by Market Capitalization
Companies near Molecular Partners AG in the global market cap rankings as of March 18, 2026.
Key companies related to Molecular Partners AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Molecular Partners AG Historical Marketcap From 2018 to 2025
Between 2018 and today, Molecular Partners AG's market cap moved from $724.05 Million to $ 157.82 Million, with a yearly change of -21.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $157.82 Million | -6.84% |
| 2024 | $169.42 Million | +5.35% |
| 2023 | $160.82 Million | -30.31% |
| 2022 | $230.75 Million | -68.81% |
| 2021 | $739.94 Million | -16.13% |
| 2020 | $882.25 Million | +67.30% |
| 2019 | $527.33 Million | -27.17% |
| 2018 | $724.05 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Molecular Partners AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $157.82 Million USD |
| MoneyControl | $157.82 Million USD |
| MarketWatch | $157.82 Million USD |
| marketcap.company | $157.82 Million USD |
| Reuters | $157.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.